ストックスクリーナーアプリを入手
1.82
0.55%
0.01
アフターアワーズ：
1.80
-0.02
-1.10%
前日終値:
$1.81
開ける：
$1.88
24時間の取引高:
70,583
Relative Volume:
0.37
時価総額：
$31.95M
収益：
$411.00K
当期純損益:
$-4.85M
株価収益率:
-4.1364
EPS:
-0.44
ネットキャッシュフロー:
$-4.88M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-17.27%
6か月 パフォーマンス:
-50.41%
1年 パフォーマンス:
+22.97%
1日の値動き範囲:
$1.75
$1.90
1週間の範囲:
$1.67
$1.90
52週間の値動き範囲:
$1.4271
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
名前
Lexaria Bioscience Corp
セクター
電話
250-765-6424
住所
100 - 740 MCCURDY ROAD, KELOWNA
LEXX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.82 | 31.95M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexaria Bioscience Corp (LEXX) 最新ニュース
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks
Lexaria reports promising drug delivery study results - Investing.com
GLP-1 Game-Changer: This Small Biotech Found How to Slash Semaglutide Side Effects by 60% - StockTitan
What is Zacks Small Cap’s Estimate for LEXX Q4 Earnings? - Defense World
LEXX: IRB Approval Clears Way for GLP-1 Study #5 - Yahoo Finance
HC Wainwright Has Lowered Expectations for Lexaria Bioscience (NASDAQ:LEXX) Stock Price - Defense World
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright - Investing.com
Lexaria Bioscience Holds Successful Shareholder Meeting; Votes in New Directors and Approves Proposals - Defense World
Lexaria Bioscience shareholders approve board and auditor selections - Investing.com
Lexaria Bioscience Advances with Human Study for Oral Liraglutide - TipRanks
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval - WICZ
Lexaria Gets Green Light for Oral Weight Loss Drug Trial, Aims to Replace Saxenda Injections - StockTitan
Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection - TipRanks
Lexaria's Oral GLP-1 Drug Shows 47% Fewer Side Effects Than Injectable Zepbound in Clinical Study - StockTitan
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2024 - Marketscreener.com
Lexaria Bioscience Earnings Analysis: Q1 Recap - Benzinga
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
NRx Pharmaceuticals (NASDAQ:NRXP) and Lexaria Bioscience (NASDAQ:LEXX) Head to Head Contrast - Defense World
Lexaria Bioscience Announces Executive Management Agreement ChangesLexaria Bioscience Corp. (OTCMKTS:LXRP) recently disclosed key alterations to its Executive Management Agreement in a current report filed with the Securities and Exchange Com - Defense World
HighTower Advisors LLC Takes Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
H.C. Wainwright maintains Buy rating on Lexaria Bioscience stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Buy rating on Lexaria Bioscience stock - Investing.com
Lexaria Bioscience Corp. (NASDAQ:LEXX) Shares Bought by XTX Topco Ltd - Defense World
Lexaria Bioscience Launches Key Phase 1b Trial Testing DehydraTECH Enhancement of GLP-1 Drugs - StockTitan
Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com Australia
Lexaria Bioscience finalizes clinical study agreement - Investing.com
Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com
Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan
Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance
Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance
LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com
LEXX: Phase I Start Imminent - Yahoo Finance
Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World
LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com
Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com
Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria
Lexaria Bioscience CEO buys $118,391 in shares - Investing.com
Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World
Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com
LEXXW (Lexaria Bioscience) 3-Year Revenue Growth Rate : -39.20% (As of Aug. 2024) - GuruFocus.com
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Markets Insider
Lexaria's DehydraTECH Breakthrough: Fox Business to Spotlight Drug Delivery Innovation | LEXX Stock News - StockTitan
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Lexaria Bioscience Corp (LEXX) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):